“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at ruxolitinib for polycythaemia vera (The RESPONSE trial)
Coronavirus and cancer
We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.
This trial looked at ruxolitinib (INC424) for people with polycythaemia vera who didn’t respond to standard treatment.
More about this trial
Polycythaemia vera is a myeloproliferative disorder. This is a condition where the
Doctors treat polycythaemia vera with drugs such as hydroxycarbamide (hydroxyurea). This can control the number of blood cells. But sometimes hydroxycarbamide stops working. Or people can’t carry on taking it because of unacceptable side effects.
Researchers looked for new treatments to help these people.
In this trial they looked at ruxolitinib. It blocks the action of the JAK2 enzyme and might reduce the number of red blood cells. The aims of the study were to
- find if ruxolitinib helped people with polycythaemia vera
- learn more about the side effects
Summary of results
The trial team found that ruxolitinib was better than standard treatment for people with polycythaemia vera (PV).
- 110 people had ruxolitinib
- 112 people had standard treatment
The team looked at 2 signs of PV to see what the response to treatment was
- size of the
- a blood test looking at the level of haematocrit
People who have PV have an enlarged spleen. They also have a high level of haematocrit.
After 32 weeks of treatment the team wanted to see how many people’s spleen had reduced in size by at least 35%. And whose haematocrit level was under control.
For reduction in spleen size it was
- 38 out of every 100 people (38%) had ruxolitinib
- 1 out of every 100 people (1%) had standard treatment
For control of haematocrit level it was
- 60 out of every 100 people (60%) had ruxolitinib
- 20 out of every 100 people (20%) had standard treatment
The most common side effects of ruxolitinib were
- a drop in blood cells
- muscle spasms
- shortness of breath
- tummy (abdominal) pain
The trial team concluded that ruxolitinib was better than standard treatment for PV at
- controlling the haematocrit level
- reducing the size of the spleen
- improving the symptoms of PV
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
NIHR Clinical Research Network: Cancer